Compugen Ltd
CGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$233.55M
Close$
$2.54
2.9% upside
Current Fair Value
2.9% upsideUndervalued by 2.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $233.55 Million |
|---|---|
| Enterprise Value | $237.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.38 |
| Beta | 2.79 |
| Outstanding Shares | 94,640,696 |
Return
| Return on Equity | 39.66% |
|---|---|
| Return on Assets | 25.43% |
| Return on Invested Capital | 29.76% |
Valuation & Multiples
| P/E Ratio | 6.58 |
|---|---|
| PEG | -143.77 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.21 |
| Enterprise Value to EBIT | 6.9 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.4422▲ 144.22% |
|---|---|
| Total Calls | 100,400▼ 18.97% |
| Total Puts | 144,800▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.93%▼ 0.09% |
|---|---|
| Total Invested | $30.24M▼ 2.12% |
| Investors Holding | 86▲ 5.00% |
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...